Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796

Links shared publicly online about this topic.

  • 1,274
    total visits

Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796

medicalnewstoday.com —

Depomed, Inc. (NASDAQ: DEPO) announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic ne

View full resource at medicalnewstoday.com

Tags: Pain, Drug, FDA

  • Share

Most Recently Shared on March 31, 2010 at 10:07 pm By:

mnt_pain MNT Pain News

Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796 http://mnt.to/3zHg #pain

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

medical_tweets medical_tweets

Advertisement